☆ 4.7 Editorial Material

CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?

LANCET ONCOLOGY (2019)

Journal

LANCET ONCOLOGY

Volume 20, Issue 11, Pages 1479-1481

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/S1470-2045(19)30627-8

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer

Runtian Wang, Kun Xu, Fangyan Gao, Jinyi Huang, Xiaoxiang Guan

Summary: The formation of cyclinD-CDK4/6 complex is essential for the cell cycle transition from G1 phase to S phase. CDK4/6 inhibitors can block cell cycle progression and proliferation, showing promising effects in containing the aggressiveness of breast cancers, particularly in triple-negative breast cancer.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)

Add to Collection

Article Multidisciplinary Sciences

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition

Melina Beykou, Mar Arias-Garcia, Theodoros I. Roumeliotis, Jyoti S. Choudhary, Nicolas Moser, Pantelis Georgiou, Chris Bakal

Summary: Palbociclib treatment can induce a senescence-like cell state in TNBC cells, providing insights for the future use of CDK4/6 inhibitors and the development of combination therapies in TNBC subtypes.

SCIENTIFIC DATA (2022)

Add to Collection

Article Oncology

Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Wen -Ting Peng, Xi Jin, Xiao-En Xu, Yun-Song Yang, Ding Ma, Zhi-Ming Shao, Yi-Zhou Jiang

Summary: This study identifies ACAA1 as a potential therapeutic target for TNBC, specifically in the LAR subtype. Inhibition of ACAA1 can suppress TNBC proliferation and enhance the response to abemaciclib. The combination of trimetazidine and abemaciclib shows promise in treating ACAA1-high TNBCs.

CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

Xiuzhi Zhu, Li Chen, Binhao Huang, Xiaoguang Li, Liu Yang, Xin Hu, Yizhou Jiang, Zhimin Shao, Zhonghua Wang

Summary: The combination of PARPi olaparib and CDK4/6i palbociclib shows synergistic effects against BRCA(mut)/TNBC, especially in cells resistant to olaparib, by inhibiting HR repair, increasing DNA damage, and suppressing tumor growth.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo

Lubaid Saleh, Penelope D. Ottewell, Janet E. Brown, Steve L. Wood, Nichola J. Brown, Caroline Wilson, Catherine Park, Simak Ali, Ingunn Holen

Summary: CDK4/6 inhibitor palbociclib significantly impedes tumour growth in murine models of both estrogen receptor positive and triple negative bone metastatic breast cancer when given daily. However, tumour cells become insensitive to palbociclib after a treatment break, and the levels of key proteins may play a role in this.

CANCERS (2023)

Add to Collection

Article Biology

FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway

Guanglei Chen, Lisha Sun, Xi Gu, Liping Ai, Jie Yang, Zhan Zhang, Pengjie Hou, Yining Wang, Xunyan Ou, Xiaofan Jiang, Xinbo Qiao, Qingtian Ma, Nan Niu, Jinqi Xue, Hao Zhang, Yongliang Yang, Caigang Liu

Summary: The expression level of FSIP1 can predict the treatment response of TNBC to CDK4/6 inhibitors. High FSIP1 expression is associated with poor prognosis and increased tumor cell proliferation. FSIP1 downregulation slows tumor growth and reduces lung metastasis in TNBC, and its knockout leads to cell cycle arrest and reduced sensitivity to CDK4/6 inhibitors.

SCIENCE CHINA-LIFE SCIENCES (2023)

Add to Collection

Review Oncology

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Ye Hu, Jiyue Gao, Meiling Wang, Man Li

Summary: CDK4/6 inhibitors may offer an effective treatment option for triple-negative breast cancer, but their efficacy in patients is still uncertain. Combining them with other targeted therapies may improve patient outcomes and treatment effects. Identifying biomarkers for response or resistance to CDK4/6 inhibitor treatment can personalize treatment strategies.

CANCER MANAGEMENT AND RESEARCH (2021)

Add to Collection

Article Pharmacology & Pharmacy

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer

Jiahao Qiu, Xinfa Bai, Wenjing Zhang, Mingxu Ma, Wenyan Wang, Ye Liang, Hongbo Wang, Jingwei Tian, Pengfei Yu

Summary: This study developed a CDK4/6 degrader against TNBC using hydrophobic tagging technology and demonstrated its efficacy and safety through in vitro and in vivo experiments. This suggests the potential of using hydrophobic tags as a strategy to treat TNBC.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Oncology

The role of CDK4/6 inhibitors in early breast cancer

Miguel Gil-Gil, Emilio Alba, Joaquin Gavila, Juan de la Haba-Rodriguez, Eva Ciruelos, Pablo Tolosa, Daniele Candini, Antonio Llombart-Cussac

Summary: The article reviews the use of CDK4/6 inhibitors in the treatment of early breast cancer, including neoadjuvant and adjuvant settings. Evaluation of recent large phase 3 adjuvant trial results, examination of biomarkers as response predictive factors, and discussion on the combination of CDK4/6i and radiotherapy are included in the review.

BREAST (2021)

Add to Collection

Article Oncology

C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer

Li Liao, Ling Deng, Yin-Ling Zhang, Shao-Ying Yang, Lisa Andriani, Shu-Yuan Hu, Fang-Lin Zhang, Zhi-Min Shao, Da-Qiang Li

Summary: C9orf142 is elevated in TNBC patients and its elevation predicts unfavorable clinical outcome. C9orf142 promotes TNBC progression through transcriptional activation of MTBP to regulate its downstream MDM2/p53/p21 signaling axis. C9orf142 enhances resistance of TNBC cells to CDK4/6 inhibitor partially through MTBP/MDM2/p53/p21 signaling axis. Knockdown of C9orf142 inhibits TNBC progression and enhances its sensitivity to CDK4/6 inhibitor.

CLINICAL AND TRANSLATIONAL MEDICINE (2023)

Add to Collection

Review Medicine, Research & Experimental

Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: Epigenetic mnemonics

Janice Jacson Mandumpala, Stephin Baby, Antriya Annie Tom, Chandraiah Godugu, Nagula Shankaraiah

Summary: Triple-negative breast cancer (TNBC) is a highly lethal subtype of breast cancer with limited treatment options due to its complexity, drug resistance, and lack of therapeutic targets. Recent studies have shown the importance of epigenetic regulation in TNBC development, with a focus on histone methyltransferases and histone demethylases as potential targets for new targeted therapies in TNBC treatment.

LIFE SCIENCES (2022)

Add to Collection

Review Oncology

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer

Ilenia Migliaccio, Angela Leo, Francesca Galardi, Cristina Guarducci, Giulio Maria Fusco, Matteo Benelli, Angelo Di Leo, Laura Biganzoli, Luca Malorni

Summary: This review discusses recent achievements in the development of circulating biomarkers in patients with metastatic breast cancer treated with CDK4/6 inhibitors and endocrine therapy. Circulating biomarkers have the potential advantages of recognizing patients who might not respond to treatment and monitoring treatment effects with a simple withdrawal of peripheral blood.Various circulating markers are currently being tested for their potential to predict response to CDK4/6 inhibitors treatment in patients with HR+/HER2- breast cancer.

CANCERS (2021)

Add to Collection

Review Health Care Sciences & Services

Investigational Drug Treatments for Triple-Negative Breast Cancer

Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Konstantinos Nikolettos, Panagiotis Sarantis, Vasiliki E. Georgakopoulou, Afroditi Nonni, Dimitrios Schizas, Efstathios A. Antoniou, Michalis Karamouzis, Nikos Nikolettos, Konstantinos Kontzoglou, Alexandros Patsouras, Errika Voutyritsa, Athanasios Syllaios, Evangelos Koustas, Nikolaos Trakas, Dimitrios Dimitroulis

Summary: Triple-negative breast cancer is an aggressive subtype of breast cancer that does not respond well to hormone therapy but often shows good response to chemotherapy. It is important to investigate new beneficial targeted therapies in order to achieve enhanced outcomes for patients.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Review Medicine, Research & Experimental

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer

Lubaid Saleh, Caroline Wilson, Ingunn Holen

Summary: TNBC is a subtype of breast cancer that lacks expression of hormone receptors and is associated with poorer prognoses compared to other types of breast cancer. Conventional chemotherapeutics are used to manage TNBC, but systemic relapse is common with limited benefits and adverse events documented.

MEDCOMM (2021)

Add to Collection

Article Multidisciplinary Sciences

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells

Edris Choupani, Zahra Madjd, Neda Saraygord-Afshari, Jafar Kiani, Arshad Hosseini

Summary: This study investigates the possibility of combining CDK4/6 inhibitor and AR inhibitor in AR-positive TNBC cells. The results show that this combination treatment has a good effect in inhibiting cell migration, clonogenic capacity, cell cycle progression, and cell growth, leading to improved therapeutic outcomes.

PLOS ONE (2022)

Add to Collection

Article Oncology

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M. Tolaney, Andrew M. Wardley, Stefania Zambelli, John F. Hilton, Tiffany A. Troso-Sandoval, Francesco Ricci, Seock-Ah Im, Sung-Bae Kim, Stephen R. D. Johnston, Arlene Chan, Shom Goel, Kristen Catron, Sonya C. Chapman, Gregory L. Price, Zhengyu Yang, M. Corona Gainford, Fabrice Andre

LANCET ONCOLOGY (2020)

Add to Collection

Editorial Material Oncology

Trastuzumab-related cardiotoxicity: what do we know in 2020?

Jia Liu, Shom Goel, Jane McNeil Beith

TRANSLATIONAL CANCER RESEARCH (2020)

Add to Collection

Review Oncology

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jan Hudecek, Leonie Voorwerk, Maartje van Seijen, Iris Nederlof, Michiel de Maaker, Jose van den Berg, Koen K. van de Vijver, Karolina Sikorska, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O. Nielsen, Sunil S. Badve, Stefan Michiels, William Fraser Symmans, Christos Sotiriou, David L. Rimm, Stephen M. Hewitt, Carsten Denkert, Sibylle Loibl, Sherene Loi, John M. S. Bartlett, Giancarlo Pruneri, Deborah A. Dillon, Maggie C. U. Cheang, Andrew Tutt, Jacqueline A. Hall, Zuzana Kos, Roberto Salgado, Marleen Kok, Hugo M. Horlings

NPJ BREAST CANCER (2020)

Add to Collection

Review Oncology

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Mohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, Jeppe Thagaard, Weijie Chen, Sarah Dudgeon, Ashish Sharma, Jennifer K. Kerner, Carsten Denkert, Yinyin Yuan, Khalid AbdulJabbar, Stephan Wienert, Peter Savas, Leonie Voorwerk, Andrew H. Beck, Anant Madabhushi, Johan Hartman, Manu M. Sebastian, Hugo M. Horlings, Jan Hudecek, Francesco Ciompi, David A. Moore, Rajendra Singh, Elvire Roblin, Marcelo Luiz Balancin, Marie-Christine Mathieu, Jochen K. Lennerz, Pawan Kirtani, I-Chun Chen, Jeremy P. Braybrooke, Giancarlo Pruneri, Sandra Demaria, Sylvia Adams, Stuart J. Schnitt, Sunil R. Lakhani, Federico Rojo, Laura Comerma, Sunil S. Badve, Mehrnoush Khojasteh, W. Fraser Symmans, Christos Sotiriou, Paula Gonzalez-Ericsson, Katherine L. Pogue-Geile, Rim S. Kim, David L. Rimm, Giuseppe Viale, Stephen M. Hewitt, John M. S. Bartlett, Frederique Penault-Llorca, Shom Goel, Huang-Chun Lien, Sibylle Loibl, Zuzana Kos, Sherene Loi, Matthew G. Hanna, Stefan Michiels, Marleen Kok, Torsten O. Nielsen, Alexander J. Lazar, Zsuzsanna Bago-Horvath, Loes F. S. Kooreman, Jeroen A. W. M. van der Laak, Joel Saltz, Brandon D. Gallas, Uday Kurkure, Michael Barnes, Roberto Salgado, Lee A. D. Cooper

NPJ BREAST CANCER (2020)

Add to Collection

Editorial Material Cell Biology

Transforming growth factor β in breast cancer: another new trick for the old dog

Kun-Hui Lu, Shom Goel

IMMUNOLOGY AND CELL BIOLOGY (2021)

Add to Collection

Review Oncology

Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature

Steven David, Gwo Ho, Daphne Day, Marion Harris, Jennifer Tan, Shom Goel, Gerard G. Hanna, Ranjana Srivastava, Gill Kruss, Lachlan McDowell, Michelle White

Summary: Current first-line treatment for metastatic hormone receptor-positive, HER-2 negative breast cancer includes aromatase inhibitors and CDK 4/6 inhibitors, however, combining a CDK 4/6 inhibitor with palliative RT may enhance radiation toxicity. Further studies are needed to clarify the potential toxicities of this combination.

TRANSLATIONAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)

Reem Alomran, Michelle White, Melissa Bruce, Mathias Bressel, Susan Roache, Lama Karroum, Gerard G. Hanna, Shankar Siva, Shom Goel, Steven David

Summary: The increased understanding of cancer biology has led to significant advancements in systemic therapy for advanced breast cancer. Adding CDK 4/6 inhibitors to endocrine therapy has shown improved outcomes for patients with advanced ER-positive HER2-negative breast cancer, but disease progression is common. Stereotactic radiotherapy (SRT) has emerged as a safe and effective treatment for limited metastatic sites, prompting investigation into its role in oligoprogressive breast cancer.

BMC CANCER (2021)

Add to Collection

Article Oncology

Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx(R) Digital Spatial Profiler

Helga Bergholtz, Jodi M. Carter, Alessandra Cesano, Maggie Chon U. Cheang, Sarah E. Church, Prajan Divakar, Christopher A. Fuhrman, Shom Goel, Jingjing Gong, Jennifer L. Guerriero, Margaret L. Hoang, E. Shelley Hwang, Hellen Kuasne, Jinho Lee, Yan Liang, Elizabeth A. Mittendorf, Jessica Perez, Aleix Prat, Lajos Pusztai, Jason W. Reeves, Yasser Riazalhosseini, Jennifer K. Richer, Ozgur Sahin, Hiromi Sato, Ilana Schlam, Therese Sorlie, Daniel G. Stover, Sandra M. Swain, Alexander Swarbrick, E. Aubrey Thompson, Sara M. Tolaney, Sarah E. Warren

Summary: Breast cancer is a heterogeneous disease with high variability in tumor cells and the surrounding tumor microenvironment. Understanding the molecular diversity in breast cancer is crucial for predicting therapeutic response and prognosis. High-plex spatial profiling of tumors allows for characterization of heterogeneity in the breast TME, providing insights into tumor biology and response to therapy. The GeoMx Digital Spatial Profiler (DSP) enables spatial analysis of proteins and RNA transcripts, offering a valuable tool for biomarker discovery and data integration in cancer research.

CANCERS (2021)

Add to Collection

Article Oncology

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

Laura M. Spring, Shealagh L. Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J. Isakoff, Erica Mayer, Beverly Moy, Jeffrey G. Supko, Sara M. Tolaney, Aditya Bardia

Summary: This study aimed to evaluate the tolerability and efficacy of ribociclib in combination with T-DM1 in patients with HER2-positive breast cancer, and 400 mg was determined to be the recommended phase 2 dose for ribociclib based on the clinical trial.

NPJ BREAST CANCER (2021)

Add to Collection

Review Oncology

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Khalid El Bairi, Harry R. Haynes, Elizabeth Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner, Juliana Ribeiro de Freitas, Daniel Sur, Luis Claudio Amendola, Masoumeh Gharib, Amine Kallala, Indu Arun, Farid Azmoudeh-Ardalan, Luciana Fujimoto, Luz F. Sua, Shi-Wei Liu, Huang-Chun Lien, Pawan Kirtani, Marcelo Balancin, Hicham El Attar, Prerna Guleria, Wenxian Yang, Emad Shash, I-Chun Chen, Veronica Bautista, Jose Fernando Do Prado Moura, Bernardo L. Rapoport, Carlos Castaneda, Eunice Spengler, Gabriela Acosta-Haab, Isabel Frahm, Joselyn Sanchez, Miluska Castillo, Najat Bouchmaa, Reena R. Md Zin, Ruohong Shui, Timothy Onyuma, Wentao Yang, Zaheed Husain, Karen Willard-Gallo, An Coosemans, Edith A. Perez, Elena Provenzano, Paula Gonzalez Ericsson, Eduardo Richardet, Ravi Mehrotra, Sandra Sarancone, Anna Ehinger, David L. Rimm, John M. S. Bartlett, Giuseppe Viale, Carsten Denkert, Akira I. Hida, Christos Sotiriou, Sibylle Loibl, Stephen M. Hewitt, Sunil Badve, William Fraser Symmans, Rim S. Kim, Giancarlo Pruneri, Shom Goel, Prudence A. Francis, Gloria Inurrigarro, Rin Yamaguchi, Hernan Garcia-Rivello, Hugo Horlings, Said Afqir, Roberto Salgado, Sylvia Adams, Marleen Kok, Maria Vittoria Dieci, Stefan Michiels, Sandra Demaria, Sherene Loi

Summary: The use of immune-checkpoint inhibitors has significantly improved survival in cancer patients, including a subgroup of women with breast cancer who may benefit from this treatment. Studies have shown that tumor-infiltrating lymphocytes are associated with response to both cytotoxic treatments and immunotherapy, particularly in patients with triple-negative breast cancer.

NPJ BREAST CANCER (2021)

Add to Collection

Article Oncology

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2

Shom Goel, Antoinette R. Tan, Hope S. Rugo, Philippe Aftimos, Zoran Andric, Andrew Beelen, Jingshan Zhang, John S. Yi, Rajesh Malik, Joyce O'Shaughnessy

Summary: Trilaciclib, a cyclin-dependent kinase 4/6 inhibitor, has shown promising results in improving overall survival in patients with triple-negative breast cancer (TNBC) when administered prior to chemotherapy. It protects hematopoietic stem and progenitor cells and immune cells from chemotherapy-induced damage, while enhancing immune activity. The ongoing phase III trial, PRESERVE 2, aims to evaluate the efficacy and safety of Trilaciclib in patients with locally advanced unresectable or metastatic TNBC.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Immunology

PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer

Lestat R. Ali, Ana C. Garrido-Castro, Patrick J. Lenehan, Naima Bollenrucher, Courtney T. Stump, Michael Dougan, Shom Goel, Geoffrey I. Shapiro, Sara M. Tolaney, Stephanie K. Dougan

Summary: The authors analyzed blood and tumors from breast and ovarian cancer patients treated with PD-1 blockade and CDK4/6 inhibition using single-cell RNA-sequencing and TCR tracking. They found that both therapies enhance T cell effector function and memory. In mouse models of melanoma and breast cancer, the augmentation of the antitumor memory pool by ribociclib boosts the efficacy of subsequent PD-1 blockade, suggesting sequential therapy as a potentially safe and synergistic strategy in patients.

JOURNAL OF EXPERIMENTAL MEDICINE (2023)

Add to Collection

Review Oncology

Targeting CDK4 and CDK6 in cancer

Shom Goel, Johann S. Bergholz, Jean J. Zhao

Summary: Dysregulation of CDK4 and CDK6 promotes the growth and survival of several cancer types. CDK4/6 inhibitors have become the standard of care for advanced hormone receptor-positive breast cancer. Better understanding of their mechanisms of action and exploring new therapeutic opportunities are crucial.

NATURE REVIEWS CANCER (2022)

Add to Collection

Review Oncology

Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer

April C. Watt, Shom Goel

Summary: Pharmacological inhibitors of CDK4/6 are standard therapies for hormone receptor-positive breast cancer, primarily by suppressing tumor cell proliferation. Recent data suggests that these inhibitors also have other effects in tumor and stromal compartments, which may explain their clinical activity.

BREAST CANCER RESEARCH (2022)

Add to Collection

Article Oncology

CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity

April C. Watt, Paloma Cejas, Molly J. DeCristo, Otto Metzger-Filho, Enid Y. N. Lam, Xintao Qiu, Haley BrinJones, Nikolas Kesten, Rhiannon Coulson, Alba Font-Tello, Klothilda Lim, Raga Vadhi, Veerle W. Daniels, Joan Montero, Len Taing, Clifford A. Meyer, Omer Gilan, Charles C. Bell, Keegan D. Korthauer, Claudia Giambartolomei, Bogdan Pasaniuc, Ji-Heui Seo, Matthew L. Freedman, Cynthia Ma, Matthew J. Ellis, Ian Krop, Eric Winer, Anthony Letai, Myles Brown, Mark A. Dawson, Henry W. Long, Jean J. Zhao, Shom Goel

Summary: Goel and colleagues demonstrate that CDK4/6 inhibitors induce global chromatin changes in breast cancer cells by activating a wide range of enhancers, leading to biological effects such as cell differentiation and apoptotic evasion. This study provides insights into the molecular mechanisms underlying the effects of CDK4/6 inhibition and highlights the potential for further development of CDK4/6 inhibitors.

NATURE CANCER (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.